These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

231 related items for PubMed ID: 7438321

  • 1. Pharmacokinetics of hypoxic cell radiosensitizers: a review.
    Workman P.
    Cancer Clin Trials; 1980; 3(3):237-51. PubMed ID: 7438321
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics and tumor and neural tissue penetrating properties of SR-2508 and SR-2555 in the dog--hydrophilic radiosensitizers potentially less toxic than misonidazole.
    White RA, Workman P, Brown JM.
    Radiat Res; 1980 Dec; 84(3):542-61. PubMed ID: 6450431
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the fate of misonidazole (RO 07-0582) and its metabolite desmethylmisonidazole (RO 05-9963), two hypoxic cell radiosensitizers: penetration properties in tumor bearing rats.
    Akel G, Canal P, Mockey E, Vandevoorde E, Laurent F, Soula G.
    J Pharmacol; 1983 Dec; 14(1):67-77. PubMed ID: 6834852
    [Abstract] [Full Text] [Related]

  • 4. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R, Workman P, Owen L.
    Int J Radiat Oncol Biol Phys; 1982 Dec; 8(3-4):473-6. PubMed ID: 7107369
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of the hypoxic radiosensitizers misonidazole and demethylmisonidazole after intraperitoneal administration in humans.
    Gianni L, Jenkins JF, Greene RF, Lichter AS, Myers CE, Collins JM.
    Cancer Res; 1983 Feb; 43(2):913-6. PubMed ID: 6848201
    [Abstract] [Full Text] [Related]

  • 6. Radiosensitization, pharmacokinetics, and toxicity of a 2-nitroimidazole nucleoside (RA-263).
    Agrawal KC, Rupp WD, Rockwell S.
    Radiat Res; 1986 Feb; 105(2):227-39. PubMed ID: 3754053
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetic and metabolic studies of the hypoxic cell radiosensitizer misonidazole.
    Flockhart IR, Large P, Troup D, Malcolm SL, Marten TR.
    Xenobiotica; 1978 Feb; 8(2):97-105. PubMed ID: 415443
    [Abstract] [Full Text] [Related]

  • 8. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 9. Relationship between the neurotoxicity of the hypoxic cell radiosensitizer SR 2508 and the pharmacokinetic profile.
    Coleman CN, Halsey J, Cox RS, Hirst VK, Blaschke T, Howes AE, Wasserman TH, Urtasun RC, Pajak T, Hancock S.
    Cancer Res; 1987 Jan 01; 47(1):319-22. PubMed ID: 3024818
    [Abstract] [Full Text] [Related]

  • 10. Radiosensitizers: rationale and potential.
    Brown JM.
    Cancer Treat Rep; 1981 Jan 01; 65 Suppl 2():95-102. PubMed ID: 7346152
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The effects of misonidazole during continuous low dose rate irradiation.
    Fu KK, Hurst S, Begg AC, Brown JM.
    Cancer Clin Trials; 1980 Jan 01; 3(3):257-65. PubMed ID: 7438323
    [Abstract] [Full Text] [Related]

  • 13. Partition coefficient as a guide to the development of radiosensitizers which are less toxic than misonidazole.
    Brown JM, Workman P.
    Radiat Res; 1980 Apr 01; 82(1):171-90. PubMed ID: 7367588
    [No Abstract] [Full Text] [Related]

  • 14. The pharmacokinetics, bioavailability and biodistribution in mice of a rationally designed 2-nitroimidazole hypoxia probe SR-4554.
    Aboagye EO, Lewis AD, Graham MA, Tracy M, Kelson AB, Ryan KJ, Workman P.
    Anticancer Drug Des; 1996 Apr 01; 11(3):231-42. PubMed ID: 8663910
    [Abstract] [Full Text] [Related]

  • 15. [Plasma and tissues distribution of misonidazole (RO 07-0582) in the rat bearing a chimio induced tumor (author's transl)].
    Akel G, Canal P, Bugat R, Soula G, Combes PF.
    J Pharmacol; 1981 Apr 01; 12(4):383-91. PubMed ID: 7321570
    [Abstract] [Full Text] [Related]

  • 16. Optical isomers of a new 2-nitroimidazole nucleoside analog (PR-350 series): radiosensitization efficiency and toxicity.
    Oya N, Shibamoto Y, Sasai K, Shibata T, Murata R, Takagi T, Iwai H, Suzuki T, Abe M.
    Int J Radiat Oncol Biol Phys; 1995 Aug 30; 33(1):119-27. PubMed ID: 7642409
    [Abstract] [Full Text] [Related]

  • 17. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
    National Toxicology Program .
    Natl Toxicol Program Tech Rep Ser; 1993 Sep 30; 422():1-340. PubMed ID: 12616289
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM, Yu NY, Workman P.
    Br J Cancer; 1979 Mar 30; 39(3):310-20. PubMed ID: 465300
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics and disposition of the oxytocin receptor antagonist L-368,899 in rats and dogs.
    Thompson KL, Vincent SH, Miller RR, Colletti AE, Alvaro RF, Wallace MA, Feeney WP, Chiu SH.
    Drug Metab Dispos; 1997 Oct 30; 25(10):1113-8. PubMed ID: 9321512
    [Abstract] [Full Text] [Related]

  • 20. Dose-dependence and related studies on the pharmacokinetics of misonidazole and desmethylmisonidazole in mice.
    Workman P.
    Cancer Chemother Pharmacol; 1980 Oct 30; 5(1):27-37. PubMed ID: 7460192
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.